Hang Seng Biotech Index Futures
Introduction
Hang Seng Biotech Index (HSBIO) was launched on 16 December 2019 and tracks the performance of the 30 largest biotech companies that are listed in Hong Kong and eligible for Southbound Stock Connect.
The HSBIO is freefloat-adjusted market-capitalization weighted with a 10% cap on individual stocks.
The latest list of constituent stocks and compilation methodology are available on the website of Hang Seng Indexes Company Limited at http://www.hsi.com.hk
The Hang Seng Biotech Index Futures are the first exchange-traded derivatives contracts to track the Index. They complement HKEX’s flagship Hang Seng Index, Hang Seng China Enterprises Index and Hang Seng TECH Index products, providing investors with a unique tool to manage risks in their exposures to Hong Kong-listed biotech companies, especially given the sector’s volatile nature.
Trading Fees and Commission
Market Makers or Liquidity Providers Obligations and Incentives
For details of the Liquidity Providing Obligations and Incentives, please refer to the
circular.